Literature DB >> 35585948

Management of scleroderma gastrointestinal disease: Lights and shadows.

Jenice X Cheah1, Dinesh Khanna2, Zsuzsanna H McMahan3.   

Abstract

Gastrointestinal symptoms affect the great majority of patients with systemic sclerosis. Management of these complications is often challenging as any region of the gastrointestinal tract may be involved, and significant heterogeneity exists in clinical presentation, kinetics, and outcomes. Here, we highlight new findings relevant to the management of systemic sclerosis-related gastrointestinal disease (lights) and consider areas that we have yet to elucidate (shadows).
© The Author(s) 2022.

Entities:  

Keywords:  GI complications; SSc-related gastrointestinal disease; Systemic sclerosis; dysmotility; gastrointestinal; management; scleroderma complications

Year:  2022        PMID： 35585948      PMCID： PMC9109510          DOI： 10.1177/23971983221086343

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN： 2397-1983


  99 in total

1.  Percutaneous tibial nerve stimulation vs sacral nerve stimulation for faecal incontinence: a comparative case-matched study.

Authors:  S Al Asari; G Meurette; S Mantoo; C Kubis; V Wyart; P-A Lehur
Journal:  Colorectal Dis       Date:  2014-11       Impact factor: 3.788

2.  Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms.

Authors:  M Tauber; J Avouac; A Benahmed; L Barbot; B Coustet; A Kahan; Y Allanore
Journal:  Clin Exp Rheumatol       Date:  2014-11-03       Impact factor: 4.473

3.  Internal anal sphincter atrophy in patients with systemic sclerosis.

Authors:  Nora M Thoua; Alexis Schizas; Alastair Forbes; Christopher P Denton; Anton V Emmanuel
Journal:  Rheumatology (Oxford)       Date:  2011-04-18       Impact factor: 7.580

4.  Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.

Authors:  Adam D Farmer; James K Ruffle; Anthony R Hobson
Journal:  Neurogastroenterol Motil       Date:  2018-10-23       Impact factor: 3.598

5.  Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.

Authors:  Jasmin Raja; Svetlana I Nihtyanova; Charles D Murray; Christopher P Denton; Voon H Ong
Journal:  Rheumatology (Oxford)       Date:  2015-08-28       Impact factor: 7.580

6.  The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study.

Authors:  A Kahan; S Chaussade; M Gaudric; B Freitag; B Amor; C J Menkes; G Strauch; J Guerre; D Couturier
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

7.  Efficacy of anorectal biofeedback in scleroderma patients with fecal incontinence: a case-control study.

Authors:  Josephine Collins; Yoav Mazor; Michael Jones; John Kellow; Allison Malcolm
Journal:  Scand J Gastroenterol       Date:  2016-08-16       Impact factor: 2.423

8.  Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function.

Authors:  Jagmohan Singh; Sidney Cohen; Vaibhav Mehendiratta; Fabian Mendoza; Sergio A Jimenez; Anthony J Dimarino; Satish Rattan
Journal:  Gastroenterology       Date:  2012-08-01       Impact factor: 22.682

9.  Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.

Authors:  Zsuzsanna H McMahan; Ana E Tucker; Jamie Perin; Elizabeth R Volkmann; Subhash Kulkarni; Harvey A Ziessman; Pankaj J Pasricha; Fredrick M Wigley
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01-25       Impact factor: 4.794

10.  Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

Authors:  L Chang; W D Chey; D Drossman; T Losch-Beridon; M Wang; P Lichtlen; S Mareya
Journal:  Aliment Pharmacol Ther       Date:  2016-09-27       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.